Navigation Links
Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis
Date:7/15/2011

EDISON, N.J., July 15, 2011 /PRNewswire/ -- Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. This group of drugs has had a controversial history, starting with Baycol, a drug similar to Crestor and Zocor, touted as a "super statin" before its recall from the market. Despite numerous objections from medical researchers and reputable consumer groups due to safety concerns, the drug was approved by the FDA in August of 2003, and launched a month later. Even before their FDA approval, these drugs showed signs of being linked to serious muscle and kidney problems, including the potentially fatal, muscle-destroying condition rhabdomyolysis.

Zocor and Crestor are strongly marketed by their parent companies, Merck and AstraZeneca respectively. By early 2004, 27% of all new prescriptions for statin drugs were for Crestor. The Wall Street Journal reported:

"AstraZeneca sales force (Crestor) was making more calls to doctors than any of its competitors. Beginning in late February, reflecting the sales calls, new prescriptions of Crestor began to rise and overtook Lipitor by the beginning of March 20."

This style of pharmaceutical marketing is so effective that in 2010, the statin Lipitor was the #1 selling drug in America by unit, with Crestor at #6.

Warning-sign side effects include:

  • muscle pain, tenderness, or weakness
  • lack of energy
  • fever
  • chest pain
  • yellowing of the skin or eyes
  • pain in the upper right part of the abdomen
  • nausea
  • extreme tiredness
  • unusual bleeding or bruising
  • loss of appetite
  • flu-like symptoms
  • sore throat, chills, or other signs of infection
  • rash
  • hives
  • itching
  • difficulty breathing or swallowing
  • swelling of the face, throat tongue, lips, eyes, hands, feet, ankles, or lower legs
  • hoarseness
  • numbness or tingling in the fingers or toes

These drugs are extremely profitable for the companies that market, produce, and sell them, as well as potentially, extremely dangerous for those who pay for and consume them. Lawsuits are currently being brought against the companies producing Zocor and Crestor. Many people across America have experienced unnecessary and dangerous side-effects as a result of these drugs. One of the law offices conducting lawsuits into both Crestor and Zocor is Eichen Crutchlow Zaslow & McElroy, LLP located in Edison, New Jersey and Toms River, New Jersey, a legal group with a history of award-winning legal services in the tri-state area and nationally in matters involving catastrophic personal injury, mass torts, medical malpractice, class actions, and consumer fraud litigation. Those who have been injured by Crestor or Zocor use should not hesitate to contact a lawyer.

Contact: Angela McKillop
Amckillop@njadvocates.com
NJAdvocates.com
Tel: (732) 777-0100
Fax: (732) 248-8273


'/>"/>
SOURCE Eichen Crutchlow Zaslow & McElroy, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
6. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
7. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
8. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
9. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study
11. Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... SAN FRANCISCO , Sept. 12, 2017 /PRNewswire/ ... Lifecycle Management Solutions (VLMS), is pleased to announce ... as a member of its Board of Directors ... 2017. ValGenesis VLMS enables life science companies to ... eliminate the use of paper in this process. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
Breaking Medicine News(10 mins):